Abstract 30P
Background
Survival of breast cancer has improved and treatment related metabolic profile deterioration after neoadjuvant systemic treatment (NST) becomes important issues in cancer survivors. We sought to compare metabolic and immune changes in patients who underwent 6 months of neoadjuvant chemotherapy (NCT) and neoadjuvant endocrine therapy (NET).
Methods
Prospective, randomized, phase III trial (NEST) which compared 24 weeks of response of NCT with Adriamycin and cyclophosphamide followed by docetaxel and NET with goserelin and tamoxifen. Among them, 123 patients from NEST trial in Asan Medical Center were retrospectively reviewed to evaluate metabolic changes such as BMI, total cholesterol (TC), fasting glucose and blood pressure (BP) before/after NST and 3 years of follow up. NLR were checked before and after NST. WHO classification was used for BMI and BP was classified according to 2017 AHA guideline.
Results
The mean age of patients was 42 years old. Overweight group were significantly increased after NCT and recovered after 3 year follow up (8.2%, 12.0%, 6.9% respectively, p < 0.05). BMI changes were not observed in NET group (time p value= 0.110). The mean value of initial TC before NCT was 184.6mg/dL, 216.0 mg/dL after NCT (p < 0.05), 179.0 mg/dL after 3 years of treatment (p < 0.05, after vs 3 yrs.). In the NET group, the mean initial TC before NET was 185.0mg/dL, and decreased to 176.3 mg/dL after NET, and 179.4 mg/dL after 3 yrs follow up (p = 0.192). In the NCT group, the mean fasting glucose were significantly increased while NCT (95.2mg/dL to 108.8mg/dL, p < 0.05), and recovered after 3 year follow up (98.0 mg/dL, p < 0.05). In the NET group, the mean fasting glucose changes were not observed (97.0mg/dL, 98.4 mg/dL and 98.4 mg/dL respectively p > 0.05, all). There are no effect on HTN during NCT and NET (p > 0.05 respectively). NLR was increased from 2.0 to 4.4 after NCT (p < 0.05) and decreased from 2.1 to 1.6(p < 0.05) after NET.
Conclusions
Compared with no changes on NET, NCT causes worsening of metabolic profiles such as BMI, TC, and fasting glucose, which is recovered over 3 years. NLR was increased after NCT but decreased after NET.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
15P - Comparing the outcomes of the mastectomy using the tumescent technique by between the special and non-special surgeons
Presenter: Naoya Takeda
Session: Poster display session
Resources:
Abstract
16P - Risk factors and prognostic value of non-alcoholic fatty liver disease (NAFLD) in hormone positive, non-metastatic breast cancer receiving adjuvant hormonal therapy
Presenter: Kartika Taroeno Hariadi
Session: Poster display session
Resources:
Abstract
17P - Distance related outcome in indigenous and non-indigenous breast cancer women of Western Australia
Presenter: Azim Khan
Session: Poster display session
Resources:
Abstract
18P - Usefulness of neutrophil to lymphocyte ratio in early stage breast cancer as predictor of disease-free survival in a Babylon Oncology Center
Presenter: Yaala Raof Al-Bairmany
Session: Poster display session
Resources:
Abstract
19P - Silymarin functionalized quantum cores as selective inhibitor of polo-like kinase 1, and preclinical antitumor activity in human breast cancer xenografts
Presenter: Manickam Paulpandi
Session: Poster display session
Resources:
Abstract
20P - Diagnostic value of serum HER-2 level in compression with tissue HER-2 in breast cancer: A systematic review and meta-analysis
Presenter: Amir Shamshirian
Session: Poster display session
Resources:
Abstract
21P - Clinical outcome of treatment without trastuzumab in HER2 positive breast cancer patients
Presenter: Than Than Aye
Session: Poster display session
Resources:
Abstract
22P - Clinical outcomes after skin-sparing or nipple areolar complex-sparing mastectomy with sentinel lymph node biopsy in early breast cancer patients
Presenter: Hye Yoon Lee
Session: Poster display session
Resources:
Abstract
23P - The correlations between knowledge and attitudes of productive age women toward “SADARI” (breast self-assessment) as early detection of breast cancer in Pejeng Kaja Village, Ubud, Bali
Presenter: Yorky Brahmantya
Session: Poster display session
Resources:
Abstract
24TiP - KEYNOTE-756: A randomized, double-blind, phase III study of pembrolizumab or placebo with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage, ER+/HER2−breast cancer
Presenter: Fatima Cardoso
Session: Poster display session
Resources:
Abstract